HIV 1 News and Research

RSS

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved a revision to the dosing recommendation to include once-daily dosing of PREZISTA® (darunavir) tablets in combination with ritonavir for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients with no darunavir resistance-associated mutations (DRV RAMs).

13 Dec 2010

Strategies for securing life insurance policy for pre-existing medical conditions

If you've ever been told that you can't buy life insurance due to a pre-existing medical condition or that your application was rated up due to one or more medical conditions, Life Quotes, Inc. offers these tips for securing a life insurance policy at a rate you can live with.

13 Dec 2010

OraSure commences enrollment in final study for FDA approval of OraQuick Rapid HIV-1/2 OTC test

OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that it has enrolled the first subject in its final phase of clinical studies for United States Food and Drug Administration ("FDA") approval of the Company's OraQuick® Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter ("OTC") market.

13 Dec 2010

New groundbreaking research advances understanding of HIV

It is estimated that 38 million people worldwide are currently infected with HIV and that 4.1 million more are added each year. For scientists to design treatment therapies that are effective over the long-term it is essential to learn more about how the virus mutates and develops resistance to medications.

13 Dec 2010

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional dendritic cells (DC) from viremic patients.

13 Dec 2010

EU, India leaders meet to discuss trade deal, some concerned deal will jeopardize drug access in developing countries

On Friday, Indian Commerce Minister Anand Sharma and EU Trade Commissioner Karel de Gucht met to "present a status report on the ongoing free trade talks" that some health advocates fear could limit the supply of generic medications in developing countries, according to Business Standard. "An EU source said the report would signal that talks had made excellent progress and should be wrapped up by early next year," according to the news service (Aiyar, 12/10).

13 Dec 2010

Young gay men taking risks - raising HIV transmission

A new study on HIV transmission in Australia reveals an alarming culture shift in which younger gay men appear more willing to take sexual risks and so become infected with the virus earlier. When comparing older men who have sex with men (MSM) with those aged under 35, the younger ones were found to be more likely to have never previously been tested for HIV and more likely to report not knowing the HIV status of regular partners. These men commonly reported inconsistent condom use with casual and regular partners.

12 Dec 2010

WFP, UNAIDS work to improve nutritional support available for people living with HIV/AIDS

The World Program Program (WFP), with the support of UNAIDS, is planning to launch "a new policy to make food and nutritional support more available to people living with HIV," VOA News reports. The agency "says the aim of [the] program is to help patients stick to their treatment, while protecting their households from further vulnerability," the news service adds.

10 Dec 2010

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

GeoVax Labs, Inc., announced today that early results from part A of an ongoing phase 2a clinical trial indicate an excellent safety profile and highly reproducible immunogenicity.

10 Dec 2010

Opinions: Questioning WHO's relevance; Reforming foreign aid; Efforts to prevent child marriage

"The WHO - for 62 years the world's go-to agency on all public health matters - is today outmoded, underfunded, and overly politicized," Jack Chow, former assistant director-general on HIV/AIDS, tuberculosis and malaria at WHO, writes in a Foreign Policy Argument where he outlines some of the major issues facing the WHO, including personnel challenges, the agency's "archaic" governance system and a "new atmosphere, where [other] organizations are taking health into their own hands."

10 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

USAID, PEPFAR and HHS welcome WHO's endorsement of rapid diagnostic test for TB

The United States welcomes the policy statement and roadmap issued today by the World Health Organization (WHO) charting the rollout of the Xpert MTB/RIF rapid diagnostic test for tuberculosis (TB) and rifampicin resistance, a proxy for multidrug resistant tuberculosis (MDR-TB).

9 Dec 2010

Conference examining family planning integration with national health strategies in Asia-Pacific countries begins

Representatives from 24 countries in Asia and the Pacific came together in Bangkok, Thailand, on Wednesday for the start of a three-day conference about population and family planning, Deutsche Presse-Agentur/M&C reports (12/8).

9 Dec 2010

VIRxSYS presents study results of VRX1116 at HIV DART 2010

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies, today presented results from a study of VRX1116 at HIV DART 2010 in Los Cabos, Mexico, showing that vaccinated monkeys challenged with highly pathogenic simian immunodeficiency virus achieve sustained viral load reduction, preservation of the immune system and increased survival compared to controls.

9 Dec 2010

WHO endorses rapid TB test

"The World Health Organization endorsed a new, rapid test for tuberculosis Wednesday that cuts the diagnosis time for patients from months to hours," CNN reports (Gray, 12/8).

8 Dec 2010

Rapid TB test endorsed by WHO

The World Health Organization (WHO) said that a new test that can detect tuberculosis (TB), including drug-resistant forms, in less than two hours could revolutionize treatment of the disease. Tuberculosis is still a major killer worldwide killing 4,700 people every day last year. The annual death toll of 1.7 million includes 380,000 people who are at particular risk because they have HIV, the virus that depresses the immune system and causes Aids.

8 Dec 2010

WHO endorses new rapid fully automated nucleic acid amplification test for TB

Today, WHO endorsed a new and novel rapid test for tuberculosis (TB), especially relevant in countries most affected by the disease. The test could revolutionize TB care and control by providing an accurate diagnosis for many patients in about 100 minutes, compared to current tests that can take up to three months to have results.

8 Dec 2010

European Commission must stop attacking generic medicines, says ITPC

On International Human Rights Day, as the European Commission (EC) and the Government of India meet in Brussels to finalise a European Union (EU)-India free trade agreement, the International Treatment Preparedness Coalition (ITPC) calls on Indian negotiators to put the right to health of its citizens and of the fifteen million HIV-positive people worldwide needing treatment above the pharmaceutical companies' interests and profits.

8 Dec 2010

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Abacavir Sulfate Tablets, 60 mg. The NDA is based on the reference listed drug Ziagen® by ViiV Healthcare.

7 Dec 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

HIV 1 News and Research

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Strategies for securing life insurance policy for pre-existing medical conditions

OraSure commences enrollment in final study for FDA approval of OraQuick Rapid HIV-1/2 OTC test

New groundbreaking research advances understanding of HIV

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

EU, India leaders meet to discuss trade deal, some concerned deal will jeopardize drug access in developing countries

Young gay men taking risks - raising HIV transmission

WFP, UNAIDS work to improve nutritional support available for people living with HIV/AIDS

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

Opinions: Questioning WHO's relevance; Reforming foreign aid; Efforts to prevent child marriage

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

USAID, PEPFAR and HHS welcome WHO's endorsement of rapid diagnostic test for TB

Conference examining family planning integration with national health strategies in Asia-Pacific countries begins

VIRxSYS presents study results of VRX1116 at HIV DART 2010

WHO endorses rapid TB test

Rapid TB test endorsed by WHO

WHO endorses new rapid fully automated nucleic acid amplification test for TB

European Commission must stop attacking generic medicines, says ITPC

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News